Transcutaneous immunization of Streptococcus suis bacterin using dissolving microneedles.

Area of Science:

• Immunology
• Biomedical Engineering
• Vaccinology

Background:

• Traditional needle injections for vaccines can cause pain and anxiety.
• Microneedle (MN) patches offer a potentially less invasive and more effective alternative for vaccine delivery.
• Streptococcus suis serotype 2 (S. suis 2) is a significant pathogen requiring effective vaccination strategies.

Purpose of the Study:

• To evaluate the efficacy of microneedle (MN) patches for delivering a Streptococcus suis 2 (S. suis 2) vaccine.
• To compare the immune response and protective efficacy of MN-based vaccination with traditional intramuscular (IM) injection.

Main Methods:

• Microneedle patches were designed to penetrate the skin to a depth of 200-250μm, targeting antigen-presenting cells.
• Mice were vaccinated using prime-boost regimens with either MN patches or IM injection.
• Immune responses, including antibody titers (IgG2a), T cell proliferation, and T_H1 cytokine production (IFN-γ, IL-12), were measured.
• Vaccine efficacy was assessed through protection against lethal S. suis 2 challenge and long-term antibody persistence.

Main Results:

• Microneedles successfully delivered vaccine antigens to the epidermis and dermis.
• MN vaccination induced significantly higher IgG2a antibody titers, T cell proliferation, and T_H1 cytokine levels compared to IM injection.
• A single dose of MN vaccination provided superior protection against lethal S. suis 2 challenge than IM vaccination.
• MN vaccination elicited long-lasting IgG2a antibody responses for up to 7 months.

Conclusions:

• Microneedle patch technology provides a superior method for delivering S. suis 2 vaccines compared to IM injection.
• MN-based vaccination enhances cellular and humoral immunity, leading to improved protection.
• MN patches represent a promising, painless, and effective vaccine delivery platform for S. suis 2 and potentially other pathogens.